Product Description
Mechanisms of Action: PD-1 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: HyaMab Biotech
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Cervical Cancer|Head and Neck Cancer|Oncology Solid Tumor Unspecified|Ovarian Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| YL-0116-002 | P2 |
Not yet recruiting |
Ovarian Cancer|Head and Neck Cancer|Cervical Cancer |
2027-08-31 |
32% |
2023-09-08 |
Primary Endpoints|Treatments |
| PE0116-Ib/II | P2 |
Recruiting |
Oncology Solid Tumor Unspecified |
2026-09-01 |
17% |
2023-12-16 |
Primary Endpoints|Start Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|